ES2360632T3 - Moduladores alostéricos del receptor a3 de adenosina. - Google Patents

Moduladores alostéricos del receptor a3 de adenosina. Download PDF

Info

Publication number
ES2360632T3
ES2360632T3 ES07763034T ES07763034T ES2360632T3 ES 2360632 T3 ES2360632 T3 ES 2360632T3 ES 07763034 T ES07763034 T ES 07763034T ES 07763034 T ES07763034 T ES 07763034T ES 2360632 T3 ES2360632 T3 ES 2360632T3
Authority
ES
Spain
Prior art keywords
imidazo
quinolin
amine
phenyl
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07763034T
Other languages
English (en)
Spanish (es)
Inventor
Aniko Goblyos
Johannes Brussee
Adriaan P. Ijzerman
Zhan-Guo Gao
Kenneth Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
US Department of Health and Human Services
Original Assignee
Universiteit Leiden
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, US Department of Health and Human Services filed Critical Universiteit Leiden
Application granted granted Critical
Publication of ES2360632T3 publication Critical patent/ES2360632T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
ES07763034T 2006-01-26 2007-01-25 Moduladores alostéricos del receptor a3 de adenosina. Active ES2360632T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76214106P 2006-01-26 2006-01-26
US762141P 2006-01-26

Publications (1)

Publication Number Publication Date
ES2360632T3 true ES2360632T3 (es) 2011-06-07

Family

ID=38116104

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07763034T Active ES2360632T3 (es) 2006-01-26 2007-01-25 Moduladores alostéricos del receptor a3 de adenosina.

Country Status (10)

Country Link
US (2) US8420664B2 (https=)
EP (1) EP1983990B1 (https=)
JP (2) JP5414277B2 (https=)
KR (1) KR101383228B1 (https=)
CN (1) CN101410114B (https=)
AT (1) ATE502640T1 (https=)
DE (1) DE602007013359D1 (https=)
DK (1) DK1983990T3 (https=)
ES (1) ES2360632T3 (https=)
WO (1) WO2007089507A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116652A1 (es) 2015-01-22 2016-07-28 Palobiofarma, S.L. Moduladores de los receptores a3 de adenosina
WO2018134464A1 (es) 2017-01-20 2018-07-26 Palobiofarma, S.L. Moduladores de los receptores a3 de adenosina

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CN101410114B (zh) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP2322525B1 (en) * 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
ES2422872T3 (es) * 2008-08-19 2013-09-16 Universiteit Leiden Moduladores alostéricos del receptor de adenosina A3
JP5849044B2 (ja) * 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
JP6140825B2 (ja) * 2012-08-09 2017-05-31 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
CA3021349A1 (en) * 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
EP4499641A1 (en) * 2022-03-29 2025-02-05 The United States of America, as represented by the Secretary, Department of Health and Human Services A3 adenosine receptor positive allosteric modulators
KR20240008807A (ko) * 2022-07-12 2024-01-19 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물
IL300132A (en) 2023-01-23 2024-08-01 Can Fite Biopharma Ltd Pancreatic cancer treatment
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
CA2305621C (en) 1997-10-03 2009-01-20 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
KR20030076633A (ko) * 2001-02-05 2003-09-26 가부시키 가이샤 오오쯔카 세이야쿠 고우죠우 트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법
US20020179549A1 (en) 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
EP1554583B1 (en) 2002-10-22 2007-08-22 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a disease state
DE602004006895T2 (de) 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
AU2005306325A1 (en) 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
CN101410114B (zh) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116652A1 (es) 2015-01-22 2016-07-28 Palobiofarma, S.L. Moduladores de los receptores a3 de adenosina
US10238637B2 (en) 2015-01-22 2019-03-26 Palobiofarma, S.L. Modulators of the adenosine A3 receptors
WO2018134464A1 (es) 2017-01-20 2018-07-26 Palobiofarma, S.L. Moduladores de los receptores a3 de adenosina

Also Published As

Publication number Publication date
EP1983990A1 (en) 2008-10-29
US9326978B2 (en) 2016-05-03
JP5414277B2 (ja) 2014-02-12
KR101383228B1 (ko) 2014-04-09
JP2009524668A (ja) 2009-07-02
ATE502640T1 (de) 2011-04-15
US20090054476A1 (en) 2009-02-26
EP1983990B1 (en) 2011-03-23
DE602007013359D1 (de) 2011-05-05
CN101410114A (zh) 2009-04-15
US20130197025A1 (en) 2013-08-01
US8420664B2 (en) 2013-04-16
JP2013253108A (ja) 2013-12-19
WO2007089507A1 (en) 2007-08-09
DK1983990T3 (da) 2011-07-11
KR20080099855A (ko) 2008-11-13
CN101410114B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
ES2360632T3 (es) Moduladores alostéricos del receptor a3 de adenosina.
US10125112B2 (en) Modulators of the relaxin receptor 1
KR101763674B1 (ko) 핵 수용체에 결합하는 물질
JP5567157B2 (ja) Ｎ置換インデノイソキノリン及びその合成
JP2009513495A (ja) 癌の治療において有効な新規のピロロジヒドロイソキノリン
JPH09500908A (ja) ジヒドロピラゾロピロール類
BRPI0909317B1 (pt) Imidazoquinolinas substituídas
TW200911817A (en) Polycyclic guanine derivatives and methods of use thereof
KR20200104873A (ko) 튜불린 억제제
KR20160012984A (ko) 벤조푸라논과 인돌 또는 아자인돌 콘쥬게이트 및 그의 제조방법과 용도
JP7092742B2 (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
ES2422872T3 (es) Moduladores alostéricos del receptor de adenosina A3
JP2006518767A (ja) フラボン酢酸類似体およびその使用方法
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
WO2013157889A1 (ko) 신규한 아미노피리딘 유도체의 암 예방 또는 치료 용도
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
WO2013041859A1 (en) Cannabinoid-2-receptor agonists
JP7766885B2 (ja) Ｔｒａｐ１阻害剤およびその用途
JP2006511551A (ja) マイトジェン活性化プロテインキナーゼ活性化プロテインキナーゼ−２の三環系アミノシアノピリジン阻害剤